Investor Alert

New York Markets Open in:

April 14, 2021, 9:49 a.m. EDT

AstraZeneca's lung cancer drug approved in China

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Sabela Ojea

AstraZeneca PLC said Wednesday that its Tagrisso medicine has been approved in China for the treatment of early lung cancer.

The U.K.-based pharmaceutical giant said Tagrisso is the first such drug to have received approval in China, as well as the only one to have shown efficacy against the disease in a global trial.

The FTSE 100 company added that the approval is based on the positive results coming from the Adaura Phase 3 trial, where Tagrisso was proven to reduce the risk of disease recurrence or death by 80%.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.